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Background: The aim of our study was to assess the prevalence of anxiety and
depression in the whole chronic obstructive pulmonary disease (COPD) population
and in subgroups according to sex and severity classification. A secondary objective
was to evaluate the possible differences between patients with and without a
significant high level of anxiety, depression, or both, and finally to find out a
correlation between psychological aspects, symptoms, functional parameters, and
quality of life (QoL).
Methods: Two hundred and two COPD patients were enrolled. Their levels of
anxiety, depression, dyspnea, and QoL were assessed using specific questionnaires.
One hundred and fourteen sex- and age-matched healthy subjects were used as the
control population.
Results: The prevalences of anxiety and depression were high (28.2% and 18.8%) in
COPD even when it was of mild degree, compared to the control group, in which the
prevalence of anxiety and depression were 6.1% and 3.5%, respectively. Female
patients had higher levels of anxiety and depression and worse symptom-related
QoL. Female patients reported a higher level of dyspnea than males for the same
level of ventilatory impairment. Dyspnea was more strongly correlated with
depression in women than in men.
Conclusions: Anxiety and depressive symptoms are common in patients affected by
COPD, even when their disease is mild in terms of FEV1 and respiratory symptoms.
Female patients appear to be more exposed to psychological impairment, which
correlates well with some specific symptomatic aspects of the disease, such asElsevier Ltd. All rights reserved.
imentale di Pneumologia, Ospedale San Paolo, Via A. di Rudinı´, 8, 20142, Milano, Italy.
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F. Di Marco et al.1768dyspnea. Psychological aspects need to be carefully assessed in COPD patients,
particularly in females.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Psychological issues, particularly anxiety and de-
pression, have received growing attention and
should not be overlooked when assessing patients’
quality of life (QoL),1,2 which is an important target
in the clinical management of a chronic irreversible
disease, such as chronic obstructive pulmonary
disease (COPD).3 To maximize QoL in patients with
COPD, psychological factors need to be carefully
assessed and addressed.1 An association between
COPD and depression has been proposed but
definitive data supporting such a theory have
previously not been provided due to the limited
number of studies, mainly on stable outpatients
also with mild to moderate disease.3,4 Some studies
evaluated the mood profile of COPD patients, but
limited observation either to elderly or hypoxemic
patients or they evaluated depression but not
anxiety.2,4–7 A recent paper which investigated
the level of psychological distress in a heteroge-
neous group of patients with COPD found that
patients with COPD experienced significantly more
psychological distress than the general population
and significantly less than psychiatric outpatients.8
The importance of psychological support as a
significant part of successful rehabilitation has
increasingly been emphasized.9 Many studies have
attempted to demonstrate the effects of drugs and
psychotherapy on anxiety, depression, and finally
physical functioning in COPD, but no definitive data
are available.10,11 One study demonstrated the
association between low compliance for inhalatory
treatment and depression.12 A surprisingly high
prevalence of anxiety and depression was reported
in one study on patients with chronic breathing
disorders, included COPD.13 However, the patients,
all veterans, were pre-screened by telephone and
patients lacking any indication of anxiety or
depression were not eligible for the study, which
would presumably result in the selection of a
population with elevated anxiety and depression.13
The aim of our study was to assess the prevalence
of anxiety and depression both in the whole COPD
population and in subgroups according to sex and
severity classification. A secondary objective was
to evaluate the possible differences between
patients with and without a significant high level
of anxiety, depression, or both, and finally to findout a correlation between psychological aspects,
symptoms, functional parameters, and QoL.Material and methods
Study design and population
In order to be included in the study, patients had to
present a well-established diagnosis of COPD
according to the American Thoracic Society criter-
ia.14 Patients treated with long-term oxygen
therapy or with a chronic severe disabling non-
pulmonary disease that would confound results
(e.g. insulin-dependent diabetes, symptomatic
cancer, chronic psychiatric illness, or dementia)
were excluded. Two hundred and ninety-five con-
secutive patients attending our Respiratory Unit
were screened, 93 met exclusion criteria and the
remaining 202 were enrolled (155 males, mean
age7SEM 6871, FEV1 5471% of predicted values) in
this prospective study. The levels of anxiety,
depression, dyspnea, and health-related QoL were
assessed in all cases using specific questionnaires.
Moreover, all patients underwent physiological
tests (spirometry by Elite DL, Medgraphics, USA
and arterial blood gas analysis by Omni S4, Roche
Diagnostics, Basel, Switzerland). COPD patients
were grouped in four severity subgroups according
to the GOLD classification,15 based on FEV1 values.
One hundred and fourteen sex- and age-matched
healthy subjects (80 males, mean7SEM age 6871)
were used as a control population. The control
subjects were selected from subjects who were
undergoing a routine annual check-up in our
hospital and had normal spirometric values in the
absence of clinically significant chronic diseases.
The hospital ethics committee approved the pro-
tocol, and all patients and controls gave their
written consent.Physiological measurements and health-
related QoL questionnaires
The variables in the study were as follows:
Anxiety: The Italian version of the State Trait
Anxiety Inventory (STAI) questionnaire contains
20 items equally divided between positive and
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range of possible scores varies from a minimum of
20 to a maximum of 80, the higher the score the
higher the level of anxiety. A cut-off value of 45 has
been used to dichotomize patients into low- and
high-anxiety groups.18 The STAI questionnaire was
used to evaluate traits of anxiety among healthy,
adult subjects, psychiatric patients, and patients
suffering from chronic heart failure, asthma, and
COPD.1,19 A high score is associated with higher-
anxiety level. Studies carried out on patients with
anxiety disorders confirmed the questionnaire’s
reliability in accurately measuring anxiety level in
comparison with the Diagnostic and Statistical
Manual of Mental Disorders (DSM) standard.20,21
Depression: The Zung22 self-rated depression
scale (SDS, Italian version) is a questionnaire that
presents 20 items with negative and positive
contents and evaluates depressive state.23 Possible
scores range from 20 to 80: the higher the score,
the higher the level of depression. This instrument
is of particular relevance in that it has been widely
used in normal persons as well as in various patient
groups, including patients suffering from chronic
respiratory diseases, making considerable valida-
tion data available as well as a large number of
comparison groups to aid in the interpretation of
the results.19,24,25 A cut-off of 50 has been
demonstrated to be sensitive in distinguishing
patients with and without depression.3,25 A study
demonstrated that, using the criteria of the DSM as
a standard, the SDS questionnaire has a sensitivity
of 97% and a specificity of 63%.26
QoL: The Italian version of St. George’s Respira-
tory Questionnaire (SGRQ) comprises 50 items and
76 weighted responses divided into three subscales:
symptoms, activity, and impact. Scores range from
0% to 100%, with 0 being the best possible score and
100% the worst.27
Dyspnea: The Italian version of the modified
Medical Resource Council (MRC) dyspnea scale
consists of five statements about perceived breath-
lessness: from grade 1 (I only get breathless with
strenuous exercise) up to grade 5 (I’m too breath-
less to leave the house).28Statistical analysis
Analysis was carried out using the Statistical
Package for Social Sciences (SPSS, Chicago, USA).
The results are shown as mean7SEM unless other-
wise stated. Quantitative variables were analysed
using analysis of variance (ANOVA) and, if positive,
post hoc comparisons were carried out by t-test
with Bonferroni adjustment. For qualitativevariables, either a w2 or a Fischer exact test was
used. The relationships between variables were
evaluated using Pearson product moment correla-
tion coefficients. As there were multiple compar-
isons, Bonferroni adjustment was used. Stepwise
multiple regression was used to identify the factors
that were most strongly related to QoL (SGRQ total
score) and to both anxiety and depression. All
variables with a P-value of o0.05 were entered
into the regression model according to stepwise
approach, while all variables with a P-value of
40.10 were removed. In order to avoid contamina-
tion, the three separate SGRQ subscales (impact,
activity, and symptoms) were excluded from the
regression analysis regarding SGRQ total score. A
P-value o0.05 was the criterion for statistical
significance.Results
Baseline characteristics of the COPD patients and
control subjects are shown in Table 1. The number
of subjects with a significant, high score for
depression and anxiety yielded prevalences in the
COPD group of 18.8% and 28.2%, respectively, while
in the control group the prevalences were 3.5% and
6.1% for depression and anxiety, respectively. The
differences in prevalence of both anxiety and
depression between the COPD and control groups
were statistically significant (Po0:001).
The distribution of studied variables according
to sex in the control group and in COPD patients
(Table 1) revealed that women had a higher level of
anxiety and depression and, in the COPD group
only, a more severe degree of dyspnea and a worse
symptom-related QoL. In light of this result, we
analysed the correlation between dyspnea and
depression in male and female patients; the
correlation was stronger in the female group
(r ¼ 0:541, Po0:001 for females and r ¼ 0:211,
Po0:05 for males).
The distribution of the studied variables accord-
ing to disease severity is shown in Table 2. ANOVA
found significant differences in terms of IC and QoL
(total score and subgroups) with a worse ventila-
tory pattern and QoL in patients with more severe
disease. No significant differences in anxiety or
depression were found.
To evaluate the possible differences between
patients with or without significant anxiety and
depression levels, we analysed the distribution of
all variables in the two groups (Table 3). Patients
with a significant, high level of anxiety showed a
higher level of depression and a worse QoL, while
ARTICLE IN PRESS
Table 1 Variables studied in COPD and control groups (whole population, males, and females).
Characteristics All Males Females P-value
COPD patients
No. participants 202 155 47 —
Age (year) 6871 6871 7071 0.135
BMI (kg/m2) 26.370.3 26.470.2 26.070.5 0.381
Disease duration (year) 971 971 871 0.808
FEV1 (%) 5471 5372 5772 0.213
IC (%) 6471 63771 6272 0.743
PaO2 (mmHg) 7472 7372 7672 0.159
Anxiety (STAI score) 39.470.6 38.570.7 41.971.4 0.024
Anxiety prevalence (%) 28.2 25.2 38.3 0.080
Depression (SDS score) 41.170.6 39.970.7 45.271.4 o0.001
Depression prevalence (%) 18.8 12.9 38.3 o0.001
Prevalence of both anxiety and depression (%) 10.9 6.5 25.5 o0.001
QoL (SGRQ total) 45.171.7 45.371.9 44.273.4 0.781
QoL (SGRQ symptoms) 57.371.8 55.372.1 64.0773.8 0.047
QoL (SGRQ activity) 33.571.5 32.571.8 36.973.0 0.216
QoL (SGRQ impact) 42.771.5 41.871.7 45.772.9 0.272
Dyspnea (MRC score) 1.970.1 1.770.1 2.470.2 0.003
Healthy subjects
No. participants 114 80 34 —
Age (year) 6571 6671 6472 0.299
Anxiety (STAI score) 34.370.5 32.970.6 37.670.9 o0.001
Anxiety prevalence (%) 6.1 3.8 11.8 0.103
Depression (SDS score) 32.570.7 30.970.8 36.371.6 0.001
Depression prevalence (%) 3.5 1.3 8.8 0.044
Prevalence of both anxiety and depression (%) 0 0 0 —
P-value, male vs. female comparison. BMI, body-mass index; IC, inspiratory capacity; QoL, quality of life.
Table 2 Characteristics of COPD patients according to the GOLD15 severity classification.
Disease severity Mild Moderate Severe Very severe P-value
FEV1X80% X50 FEV1o80 X30
FEV1o50%
FEV1o30%
No. participants 27 87 59 29
Age (year) 6672 6871 6971 6972 0.274
No. male/female gender 21/6 65/22 48/11 21/8 0.338
BMI (kg/m2) 25.970.5 26.470.3 26.870.6 25.470.5 0.291
Disease duration (year) 671 1071 871 1072 0.338
IC (%) 8371 7072 4972 5473 o0.001
PaO2 (mmHg) 8072 7272 7572 7072 0.068
Anxiety score (STAI) 36.171.9 39.271.0 40.371.1 41.471.3 0.148
Anxiety prevalence (%) 18.5 33.3 22.0 34.5 0.256
Depression score (SDS) 40.271.6 40.271.1 42.171.1 42.771.1 0.428
Depression prevalence (%) 14.8 18.4 23.7 13.8 0.636
Prevalence of both anxiety
and depression (%)
7.4 13.8 11.9 10.9 0.423
QoL (SGRQ total) 32.373.3 45.272.8 46.672.9 53.571.7 0.008
QoL (SGRQ symptoms) 44.0175.0 50.372.9 65.072.9 74.973.4 o0.001
QoL (SGRQ activity) 16.971.9 31.072.4 39.572.7 44.473.3 o0.001
QoL (SGRQ impact) 27.672.6 39.172.3 48.672.5 55.773.2 o0.001
Dyspnea (MRC score) 1.8270.35 1.7070.20 1.9270.13 2.3070.32 0.387
BMI, body-mass index; IC, inspiratory capacity; QoL, quality of life. P-values are related to ANOVA for continuous variables and
to w2 test for qualitative variables. Significant post hoc differences between FEV1 stages were as follows. IC: all comparisons but
not III–IV; SGRQ total score: I–IV; SGRQ symptoms: I–III, I–IV, II–III, II–IV; SGRQ activity: all comparisons but not II–III, III–IV; SGRQ
impact: all comparisons but not III–IV.
F. Di Marco et al.1770
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Table 3 Differences between patients with or without significant high anxiety (STAI) or depression (SDS) score.
Characteristics Anxiety (STAI score) Depression (SDS score)
X45 o44 P-value X50 o50 P-value
No. participants 57 145 38 164
No. male/female gender 39/18 116/29 0.080 20/18 135/29 o0.001
Age (year) 6771 6971 0.402 6971 6871 0.446
BMI (kg/m2) 26.570.3 26.270.3 0.521 26.770.4 26.170.3 0.359
Disease duration (year) 9.871.5 8.270.6 0.474 10.672.0 8.1570.6 0.105
FEV1 (% predicted) 5472 5472 0.954 5473 5471 0.799
IC (% predicted) 6272 6371 0.162 5973 6471 0.146
PaO2 (mmHg) 7272 7572 0.336 7272 7572 0.483
Anxiety (STAI score) 51.170.7 34.670.5 o0.001 46.671.7 37.670.6 o0.001
Depression (SDS score) 48.071.0 38.470.7 o0.001 55.270.6 37.870.5 o0.001
QoL (SGRQ total) 59.672.6 39.371.9 o0.001 56.473.4 42.471.8 0.001
QoL (SGRQ symptoms) 69.172.8 52.772.2 o0.001 70.474.0 54.372.0 0.001
QoL (SGRQ activity) 46.772.8 28.371.6 o0.001 50.473.4 29.671.6 o0.001
QoL (SGRQ impact) 55.972.4 37.671.6 o0.001 57.473.1 39.371.6 o0.001
Dyspnea (MRC score) 2.070.2 1.870.1 0.319 2.670.3 1.770.1 o0.001
P-values, higher vs. lower anxiety and depression score. BMI, body-mass index; IC, inspiratory capacity; QoL, quality of life.
Table 4 Pearson correlations between variables.
Anxiety Depression QoL total QoL
symptoms
QoL
activity
QoL impact Dyspnea FEV1
Anxiety 0.550** 0.612** 0.654** 0.669** 0.676** NS NS
Depression 0.550** 0.742** 0.648** 0.659** 0.695** 0.364** NS
QoL total 0.612** 0.742** 0.527** 0.621** 0.727** 0.250* 220**
QoL
symptoms
0.654** 0.648** 0.527** 0.783** 0.900** 0.366** 0.425**
QoL activity 0.669** 0.659** 0.621** 0.783** 0.957** 0.287** 0.394**
QoL impact 0.676** 0.695** 0.727** 0.900** 0.957** 0.322** 0.426**
Dyspnea NS 0.364** 0.250* 0.366** 0.287** 0.322** NS
FEV1 NS NS 0.220** 0.425** 0.394** 0.426** NS
IC 0.163* 0.194** 0.157* 0.450** 0.352** 0.352** 0.505* 0.705**
No consideration has been taken of the direction of correlation. NS, not significant; Po0:05; Po0:01. IC, inspiratory capacity;
QoL, quality of life.
Prevalence of anxiety and depression in COPD outpatients 1771patients with a significant, high level of depression
showed a worse QoL and a higher level of dyspnea.
There were more depressive female patients than
males (Po0:001). To evaluate the effect of the
contemporary presence of significant high depres-
sion and anxiety levels on the studied variables, we
compared the results of 22 patients (10.9% of the
total COPD sample) with depression and anxiety
scores higher than 50 and 45, respectively, with all
other patients. Patients with a contemporary
significant high score for depression and anxiety
were more frequently females (Po0:001) and had
worse QoL (SGRQ total score and three subgroups)
(Po0:001); on the other hand, no statistically
significant differences in lung function, dyspnea,and other demographic characteristics were
detected.
Pearson correlations for all the variables eval-
uated in all COPD patients are given in Table 4. The
patients’ psychological patterns were correlated
with QoL and depression, but anxiety was not
correlated with dyspnea. Both FEV1 and IC were
significantly correlated with QoL, with a higher
correlation for FEV1, except for the QoL symptoms
subgroup. IC but not FEV1 was significantly corre-
lated with dyspnea, and poorly correlated with
both with anxiety and depression. Stepwise multi-
ple regression analysis was used to identify vari-
ables that could best predict QoL, anxiety, and
depression. The anxiety, depression scores, and the
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total score for the SGRQ; anxiety, QoL (symptoms
subscale), dyspnea, and sex accounted for 43.0% of
the score for depression, while depression and QoL
(total score and activity subscale) accounted for
36.1% of the score for anxiety.Discussion
Our study investigated the prevalence of both
anxiety and depression disorders in a large popula-
tion of male and female COPD outpatients with a
wide range of disease severity. As previously
stated, a recent study by Kunik et al.13 investigated
the prevalence of anxiety and depression in a large
sample of patients with chronic breathing disor-
ders, including COPD, but the authors enrolled only
patients who reported a significant level of anxiety
and depression in a telephone screening. The
significant findings of our study are as follows: (1)
the prevalences of anxiety and depression are very
high in COPD, even when the disease is of mild or
moderate degree; (2) female patients have higher
levels of anxiety and depression and worse symp-
tom-related QoL; (3) female patients report a
higher level of dyspnea than males for the same
level of ventilatory impairment; and (4) dyspnea is
more strongly correlated with depression in
females than in males.
We found prevalences of anxiety and depression
of 28.2% and 18.8%, respectively, in the COPD
patients, which were significantly higher than those
in the control group. A study aimed at estimating
the prevalence of psychological distress in patients
attending a cancer centre in Milan (Italy), found a
16% prevalence of major depressive disorders and
generalized anxiety disorders, both evaluated
through questionnaires,29 while another study
carried out in Scotland, also in lung cancer
patients, found a higher prevalence of depression
than anxiety (22% and 9%, respectively).30 This
comparison stresses the importance of largely
undiagnosed psychological factors in COPD, in
comparison with neoplastic diseases, which are
commonly regarded as severe conditions affecting
psychological status. Our results are all the more
impressive in light of the exclusion from our study
of patients treated with long-term oxygen therapy,
who are susceptible to greater psychological
impairment than patients treated with standard
medical therapy.
The usefulness of evaluating the psychological
status of patients with mild or moderate COPD is
underlined by the comparison of the prevalences ofanxiety and depression in patients with different
levels of disease severity, even if a trend of anxiety
and depression worsening emerged between pa-
tients with a more severe bronchial obstruction
(Table 2). In fact, our study shows a stable, high
prevalence of both anxiety and depression in all
four stages of disease severity, with no significant
difference between patients affected by mild and
very severe disease. This result appears more
relevant because of the clinically significant differ-
ence in QoL between mild vs. moderate and severe
vs. very severe patients (SGRQ total score higher
than 4 units).31 In a review of the literature on the
prevalence of depression in COPD patients, van Ede
et al.3 underlined the lack of studies having
adequate sample sizes. Among all the reviewed
studies, only one had a sample size of more than
200 patients, and it was limited to hypoxemic
patients.7 In a study by van Manen et al.4 on 162
COPD patients, depression was present in 21.6% of
the whole cohort and in 25% of those subjects with
an FEV1 of less than 50%. The authors stated that
depression might have been more prevalent in their
subjects than in others because they included
patients with more severe airway obstruction. As
previously reported, our results did not confirm this
hypothesis, as the prevalence of depression was
similar in all four COPD grades.
We found that patients with a high level of
anxiety, depression, or both have a worse QoL; the
differences we found were always clinically sig-
nificant (more than 4 units in SGRQ score—Table 3).
Particularly significant is the correlation between
depression and QoL, which is consistent with the
results of Bosley et al.,32 who found that patients
who report poor QoL are more likely to be
depressed, feel unsupported by clinic staff, and
be poorly adherent to treatment. A literature
review on the prevalence of anxiety in COPD
patients reported rates of anxiety ranging from
10% to 40%.33 In our study, anxiety was significantly
correlated with QoL but, unlike depression, not
correlated with dyspnea.
As emerged from a recent review, COPD in
women is an understudied subject but is gaining
attention as a significant public health threat.34 In
our study, the analysis of variable distribution
according to sex revealed, among women, higher
levels of depression, anxiety, dyspnea, and worse
symptom-related QoL, without significant differ-
ences in lung function. A previous study of ours also
found a higher prevalence of depression in female
patients with chronic respiratory diseases.19 Anto-
nelli-Incalzi et al.35 stressed the greater suscept-
ibility of females to the negative effects of COPD on
health status (SGRQ total and impact scores), but
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been carried out. A partial confirmation of this
aspect could be the stronger association between
depression and dyspnea in females than in males. A
possible physiological explanation is suggested by
the study of Weiner et al.,36 who showed that
perception of dyspnea in asthmatic women was
significantly higher than in men who had signifi-
cantly higher maximal inspiratory pressure; inter-
estingly, the difference in perception of dyspnea
disappeared after inspiratory muscle training in
women aimed at allowing them to reach the same
level of muscle strength as asthmatic men.36
An interesting study by Yohannes et al.11 in
elderly, depressed patients with COPD found a low
acceptance of antidepressant treatment with
fluoxetine by the patients, and the authors con-
cluded that offering antidepressants to COPD
patients is not an effective strategy. In contrast,
an approach based on cognitive behavioural ther-
apy, carried out in a study on 56 patients, was able
to reduce anxious and depressive symptoms.13
We should mention some of the limitations of the
present study. First, the use of a fixed cut-off to
distinguish patients with or without anxiety and
depression can be questioned. However, this a
common limit of all questionnaires in which the
cut-off with the best sensitivity and specificity is
usually chosen. A study that used the STAI
questionnaire in elderly patients found a cut-off
higher than 45.20 Another study37 found in general
population a higher level of STAI score in females
than in males, suggesting that a different cut-off
score should be used according to gender. We
performed a new analysis using a cut-off of 50 for
females and of 45 for males. The prevalence of
anxiety in females was 31.9%, with a prevalence in
all COPD population of 26.7%. The 95th percentile
of the STAI score in our control group was 48 in
females and 44 in males, suggesting that a cut-off
level between 45 and 50 should be used for
females. Second, each questionnaire evaluates
specific anxiety or depression symptoms factors.38
Therefore, the choice of the questionnaires can
influence the results of the study. We chose the SDS
and STAI questionnaires because they showed a
good sensitivity and specificity.20,21,26 Third we
evaluated anxiety and depression through ques-
tionnaires and not through a structured interview,
due to the large size of the population evaluated
(more than 300 subjects). However, it should be
emphasized that STAI and SDS questionnaires have
been used for many years, and they are highly
sensitive and specific in detecting psychiatric
disease as diagnosed by a complex psychiatric
evaluation. Finally, as shown in Table 2, thedistribution of anxiety and depression level did
not reach the statistically significance although a
trend emerged; one explanation of this result,
which differs from some previous studies,4 is the
low number of enrolled patients with mild and very
severe disease. However, also in a recent paper of
Wagena et al.8 did not emerge a significant or
clinically relevant difference in psychological dis-
tress between patients with severe or very severe
COPD and patients with mild or moderate COPD.
In conclusion, anxiety and depressive symptoms
are common in patients affected by COPD, even
when their disease is mild in terms of FEV1 and
respiratory symptoms. Both anxiety and depression
correlate with QoL. Female patients appear to be
more susceptible to psychological impairment,
which correlates with some specific symptomatic
aspects of the disease, such as dyspnea. These
aspects have higher importance in light of the rising
prevalence of COPD in females. Psychological
aspects need to be carefully assessed in COPD
patients, particularly in females.References
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